Anxiety as a Potential Manic Activating Symptom from Spravato
Yes, anxiety can be a symptom associated with Spravato (esketamine) administration, but it is more commonly a direct adverse effect of the medication rather than a true manic activation. The FDA label explicitly lists anxiety as one of the symptoms that Spravato may produce 1, and this should be carefully distinguished from treatment-emergent hypomania or mania.
Understanding Anxiety with Spravato
The FDA label clearly states that "SPRAVATO may produce a variety of symptoms including anxiety, dysphoria, disorientation, insomnia, flashback, hallucinations, and feelings of floating, detachment and to be 'spaced out'" 1. This anxiety typically occurs:
- Acutely during or immediately after administration (within the 2-hour monitoring period)
- As part of dissociative symptoms that can cause considerable distress 2
- Transiently, resolving as the acute drug effects wear off
Importantly, research demonstrates that esketamine actually reduces anxiety symptoms in patients with treatment-resistant depression, whether or not they have comorbid anxiety disorders 3, 4. A systematic review found that esketamine is associated with sustained anxiolytic effects, particularly with repeated dosing 4.
Distinguishing Anxiety from Manic Activation
True Manic Activation Risk
The evidence regarding manic activation with Spravato is reassuring but requires vigilance:
- During acute treatment phase (twice weekly dosing): Real-world data from 45 bipolar depression patients showed zero cases of hypomania/mania during the acute series 5
- During maintenance phase: 28.9% of bipolar patients experienced hypomanic or manic episodes during long-term maintenance treatment (1 event per 2.7 patient-years), though only 1 event was severe enough to require hospitalization 5
- A naturalistic study with up to 260 weeks of follow-up found no treatment-emergent hypomania or manic symptoms, with YMRS scores actually decreasing over time 6
Key Differentiating Features
Anxiety from Spravato (acute drug effect):
- Occurs during or within 20-40 minutes of administration
- Associated with dissociative symptoms (detachment, floating sensations)
- Resolves within hours as drug effects wear off
- Responds to supportive measures (music therapy, reassurance) 2
True Manic Activation:
- Persistent elevated or irritable mood beyond the acute dosing session
- Decreased need for sleep
- Increased goal-directed activity or psychomotor agitation
- Racing thoughts, pressured speech
- Impulsive or risky behaviors
- Symptoms persist between treatment sessions
Clinical Management Algorithm
During the 2-Hour Monitoring Period:
If anxiety emerges acutely: This is likely a direct drug effect
- Provide reassurance and supportive environment
- Consider music therapy or other calming interventions 2
- Monitor for resolution as dissociative effects subside
- Document timing and severity
If anxiety persists beyond 2 hours or between sessions: Consider alternative explanations
- Assess for manic symptoms (elevated mood, decreased sleep need, increased activity)
- Evaluate for worsening depression or treatment-emergent suicidality
- Review concomitant medications that might contribute
For Patients with Bipolar Depression:
- Acute phase (first 4 weeks, twice weekly): Risk of manic switch is extremely low 5
- Maintenance phase: Increase vigilance for affective switches
- Use validated scales (YMRS) to monitor systematically 6
- Ensure mood stabilizers are optimized before and during esketamine treatment
Critical Caveats
The FDA label requires monitoring for signs of abuse and misuse 1, as anxiety can also be a withdrawal symptom with abrupt discontinuation after prolonged, frequent use. However, this is distinct from the acute anxiety that occurs during administration.
For patients with substance use history: Exercise heightened caution, as these individuals may be at greater risk for both abuse/misuse and anxiety symptoms 1.
The evidence strongly suggests that acute anxiety during Spravato administration is a common, transient adverse effect rather than a harbinger of manic activation. True manic switches are rare during acute treatment and only modestly increased during long-term maintenance, primarily in bipolar patients 5, 6. Systematic monitoring with validated scales and clear differentiation between acute drug effects and persistent mood elevation is essential for safe administration.